Gastric Cancer Adenocarcinoma Metastatic; Gastroesophageal Adenocarcinoma
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Innovent Biologics: exclusive worldwide rights secured March 2024 (restructured collaboration); Innovent eligible for commercial/sales milestones and royalties on global net sales
Indications
gastric/gastroesophageal junction cancer(Phase 1)
Status note First-in-human Phase 1 dose escalation and expansion trial ongoing (RP2D selection goal); only pipeline program in active development per this filing. Genmab oncology R&D collaboration (research-stage, evaluating ISAC concepts) is platform-level. BDC-3042 and trastuzumab imbotolimod (former lead) referenced but described as on hold or superseded, not in active development.
CEA ISAC
Stage not disclosed · ActiveModality: immune-stimulating antibody conjugate (ISAC)
Target CEA (carcinoembryonic antigen cell adhesion molecule 5)
Indications
solid tumors(Stage not disclosed)
Status note Boltbody ISAC targeting CEA, expressed in various solid tumors including colorectal, NSCLC, pancreatic and breast. Program can be quickly restarted per this filing; preclinical activity described. Filing also names a PD-L1 ISAC as similarly restartable.
Toray collaboration ISAC
Stage not disclosed · ActiveModality: immune-stimulating antibody conjugate (ISAC)
Partnerships Toray Industries: joint development and license agreement (2019) for a Boltbody ISAC using Toray's proprietary antibody; obligation through completion of first Phase 1 trial
Indications
cancer(Stage not disclosed)
Status note Collaboration product candidate; target and indication not disclosed in excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Gastric Cancer Adenocarcinoma Metastatic; Gastroesophageal Adenocarcinoma
—
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.